---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-045742"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T08:56:33.859854+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck terminates influenza A/B collaboration with Cocrystal Pharma; effective March 14, 2024

## Summary
- Merck terminated Exclusive License and Research Collaboration Agreement for influenza A/B antiviral compounds, effective March 14, 2024.
- Merck cited inability to develop compounds to meet specific program aspect; no existing conditions to continue collaboration.
- Cocrystal received $4M upfront in 2019 and was eligible for milestone payments and royalties—now forfeited.
- Pending patent applications on compounds covered by the Agreement remain in place.

## SEC filing metadata
- accession: 0001493152-23-045742
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315223045742/0001493152-23-045742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315223045742/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-045742
- JSON: https://secwatch.observer/filing/0001493152-23-045742.json
- Plain text: https://secwatch.observer/filing/0001493152-23-045742.txt

## Key facts
- Material Agreements
  Cocrystal Pharma, Inc. terminated Exclusive License and Research Collaboration Agreement with Merck Sharp & Dohme LLC (effective 2023-12-15).
  - Action: termination
  - Agreement: license
  - Counterparty: Merck Sharp & Dohme LLC
  - Effective: 2023-12-15
  source text: On December 15, 2023, Cocrystal Pharma, Inc. (the “Company”) received written notice from Merck Sharp & Dohme LLC (“Merck”) of Merck’s election to terminate the Exclusive License and Research Collaboration Agreement (the “Agreement”), dated January 2, 2019, by and between the Company and Merck, with respect to the collaboration with Merck on the development of influenza A/B antiviral compounds.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315223045742/0001493152-23-045742-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.